Overview

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the safety and tolerability of a single Subcutaneous (SC) dose of Ecallantide in children and adolescents with Hereditary Angioedema (HAE).

Phase:

Phase 2

Details

Lead Sponsor:

Mark Davis-Lorton, MD

Collaborator:

Dyax Corp.

Treatments:

Ecallantide